NeoPhore

NeoPhore was created as a spin out from Cambridge based PhoreMost. It is focused on the discovery and development of novel small molecule inhibitors to treat cancer through stimulation of the immune system. NeoPhore closed a £15.2m Series B round in March 2021.

 

Read more

BCL6 Inihibitors

The aim of the project is to discover potent small molecule inhibitors of BCL6. The project originates from the Institute of Cancer Research, London.




 

Read more

AdoRx Therapeutics Ltd

AdoRx Therapeutics is pursuing the discovery of new therapeutics for cancer based on modulation of the adenosine pathway.
AdoRx announced a partnership with Johnson and Johnson on 28th February 2019.


 

Read more

CHK1 Inhibitors

CHK1 is an important kinase in DNA damage response (DDR). The drug candidate was identified and developed at The Institute of Cancer Research, London and licensed from CPF to Sierra Oncology in September 2016.



Read more

Achilles Therapeutics

Achilles Therapeutics was founded in May 2016 to develop and commercialise patient-specific therapies that harness the immune system to destroy cancer cells. Achilles Therapeutics floated on NASDAQ in March 2021.






 

Read more

RET Inhibitors

The aim of the project is to deliver a RET selective inhibitor for the treatment of cancers with a RET activating mutation, found in 1-2% of non-small cell lung cancer (NSCLC), medullary thyroid cancer (MTC) and others. The RET project is in pre-clinical development and originates from the CRUK Manchester Institute Drug Discovery Unit and was licensed to Stemline Therapeutics in March 2019.

 

Read more

HSF1 Inhibitors

The aim of the HSF1 project is to identify small molecule inhibitors of the HSF1 pathway for the treatment of certain cancers. The HSF1 project is highly novel and originates from The Institute of Cancer Research, London. The HSF1 Project was licensed to Nuvectis Inc in May 2021





Read more

MPS1 Inhibitors

The aim of the MPS1 project is to develop a potent, selective and orally bioavailable inhibitor of MPS1 for the treatment of cancer in combination with taxane therapy. A development candidate has been identified and is in pre-clinical development. The project originates from The Institute of Cancer Research, London and was partnered with Boston Pharmaceuticals in June 2017.

 

 

Read more

Macrophage Pharma Ltd (MPL)

MPL is a company created by Sixth Element Capital driven by a dual strategy of macrophage polarization and dendritic cell (DC) activation to improve T-cell mediated killing.






 

Read more